Stanley M. Gartler Dies at 102 After Proving Tumors Can Start From 1 Cell

Q: How did a common genetic trait lead to proving the single-cell origin of all cancerous tumors?

A common X-linked trait, variation in the G6PD enzyme, gave Stanley Gartler a natural marker to show that tumors are clonal — meaning they arise from one original cell. His key insight relied on X-chromosome inactivation in women. Early in development, each female cell randomly switches off one of its two X chromosomes. In women who carried two different versions of the G6PD gene, this created a normal mosaic: some cells expressed one G6PD type, some the other. In ordinary tissue, both types should appear. Gartler and pathologist David Linder studied uterine fibroid tumors from Black women because the relevant G6PD variants were common enough in that population to make the test practical. If a tumor had grown from many cells, it should have shown the same mixed G6PD pattern seen in normal tissue. Instead, each tumor showed only one G6PD type. That uniform pattern meant all the tumor cells had descended from a single ancestor cell that had already fixed one X chromosome as active and the other as inactive. Because X-inactivation is stable and passed to daughter cells, the tumor effectively carried a lineage tag. This was the first convincing genetic proof of Theodor Boveri’s long-standing idea that tumors begin with one mutated cell and then expand. Gartler’s method did not prove every cancer behaves identically in every stage, but it established the foundational principle that tumors are monoclonal in origin.

1 articles · Updated · The New York Times · Jul 4

Stanley M. Gartler died May 25 at his home in Seattle at 102; his death was confirmed by his nephew, Dr. Richard Weiner, after going largely unreported.
In the early 1960s, Gartler helped provide the first convincing evidence that some tumors arise from a single mutated cell, advancing a long-standing theory about cancer's origins.
At the University of Washington, where he joined the faculty in 1957 and kept an active lab until 2007, he used X-chromosome inactivation and the G6PD gene to trace cell lineage in uterine fibroid tumors.
Gartler also exposed major errors involving early human cell lines, including contamination in the first collection of cells to permanently survive in laboratories, widening his impact beyond cancer research.

Sources

The New York Times7h ago

Stanley M. Gartler, Pioneer Cancer Researcher and Geneticist, Dies at 102

How did a common genetic trait lead to proving the single-cell origin of all cancerous tumors?

His 1966 discovery invalidated decades of research. How does his legacy protect today's labs from the same critical error?

Why are a late scientist's 60-year-old findings more relevant than ever for modern medical research?

The HeLa Bomb and Beyond: How Stanley Gartler’s Discoveries on Cell Line Misidentification and Cancer Clonality Shaped Modern Biomedical Research

Overview

Cell lines are essential for biomedical research, but misidentification remains a major problem even in 2026. This issue undermines the reliability of scientific findings, as an estimated 32,755 studies have used misidentified cells, and these flawed studies have been cited in about half a million other publications. Around 8.6% of all cell lines in use are misidentified, and 5% of human cell lines in peer-reviewed papers are affected. The International Cell Line Authentication Committee has documented nearly 600 confirmed misidentified cell lines. This widespread problem leads to significant scientific and economic costs, highlighting the urgent need for better authentication practices.

...

Sources

1 total

The New York Times7h ago

Stanley M. Gartler, Pioneer Cancer Researcher and Geneticist, Dies at 102

Stanley M. Gartler Dies at 102 After Proving Tumors Can Start From 1 Cell

Summary

Sources

Insights

The HeLa Bomb and Beyond: How Stanley Gartler’s Discoveries on Cell Line Misidentification and Cancer Clonality Shaped Modern Biomedical Research

Overview

Sources